<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="113120">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01630616</url>
  </required_header>
  <id_info>
    <org_study_id>0822-066</org_study_id>
    <nct_id>NCT01630616</nct_id>
  </id_info>
  <brief_title>A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)</brief_title>
  <official_title>A Single-Dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Odanacatib in Adolescents and Young Adults Treated With Glucocorticoids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of
      single doses of odanacatib in mature adolescents and young adults who are currently
      receiving glucocorticoid therapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants who Report an Adverse Event (AE)</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Time Curve from hour 0 to infinity (AUC0-inf) of Odanacatib</measure>
    <time_frame>Hour 0 (predose), and at 1, 2, 6, 8, 24, 96, 168, 240, and 336 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Time Curve from 0 to 168 hours (AUC0-168) of Odanacatib</measure>
    <time_frame>0 (predose), and at 1, 2, 6, 8, 24, 96, 168, 240, and 336 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Odanacatib</measure>
    <time_frame>0 (predose), and at 1, 2, 6, 8, 24, 96, 168, 240, and 336 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of Odanacatib</measure>
    <time_frame>0 (predose), and at 1, 2, 6, 8, 24, 96, 168, 240, and 336 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal half-life (t1/2) of Odanacatib</measure>
    <time_frame>0 (predose), and at 1, 2, 6, 8, 24, 96, 168, 240, and 336 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Inhibition of urinary aminoterminal crosslinked telopeptide of Type I collagen (uNTx/Cr)</measure>
    <time_frame>Baseline (predose Day 1) and 168 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Odanacatib 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Odanacatib 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Odanacatib</intervention_name>
    <description>single oral dose, tablets, 10 or 50 mg</description>
    <arm_group_label>Odanacatib 10 mg</arm_group_label>
    <arm_group_label>Odanacatib 50 mg</arm_group_label>
    <other_name>MK-0822</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single oral dose, tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects of reproductive potential (or other female subjects at the discretion
             of the investigator) must have negative serum pregnancy test and agree to use (and/or
             have their partner use) two (2) acceptable methods of birth control beginning at the
             prestudy visit throughout the study and until 2 weeks after the dose of study

          -  Receiving glucocorticoid therapy at a dose anticipated to be stable over the course
             of the study period

          -  X-ray evidence of closed epiphyses (growth plate) at the hand

          -  Nonsmoker

        Exclusion Criteria:

          -  Pregnant or unwilling to undergo pregnancy test

          -  History of stroke, chronic seizures, or major neurological disorder

          -  History of malignant neoplastic disease (cancer)

          -  Breastfeeding

          -  Primary growth disorder

          -  Any disease affecting the stomach or proximal small intestine resulting in
             malabsorption

          -  Received treatment which might have influenced bone turnover, including anabolic
             steroids, testosterone, calcitonin, calcitriol, alfacalcidol, excess vitamin A or
             excess vitamin D, or cyclosporine or initiation of use of birth control pills
             (estrogen-progestin combinations or progestin only, or depo provera) or other
             estrogen containing medications, or thyroid hormone unless on a stable dose for at
             least 1 month and has a normally functioning thyroid gland

          -  Previous treatment with any marketed or experimental bisphosphonate within 12 months

          -  History of, or evidence for, any clinically relevant metabolic bone disease (other
             than glucocorticoid-induced bone loss) including but not limited to primary
             hyperparathyroidism, hypoparathyroidism, hyperthyroidism, osteomalacia, and
             osteogenesis imperfecta within previous 3 years

          -  History of hypothyroidism

          -  Consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic
             beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces], wine [125
             mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day

          -  Consumes excessive amounts, defined as greater than 6 servings (1 serving is
             approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other
             caffeinated beverages per day

          -  Has had major surgery, donated or lost 1 unit of blood (approximately 500 mL), or
             participated in another investigational study within 4 weeks

          -  History of significant multiple and/or severe allergies (including latex allergy), or
             has had an anaphylactic reaction or significant intolerability to prescription or
             non-prescription drugs or food

          -  Regular user (including &quot;recreational use&quot;) of any illicit drugs, or has a history of
             drug or alcohol abuse

          -  Unable to swallow tablets
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Finland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Moldova, Republic of</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 26, 2016</lastchanged_date>
  <firstreceived_date>June 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
